Evidence map›Paper›PMID 42116040›Full record

ArticleCardiovascular diabetology2026

Evaluation of the lipid accumulation product for MASLD risk stratification in type 2 diabetes: establishing sex-specific thresholds and clinical utility.

Xiaoxiao Qu, Guanhong Li, Hongqun Tao, Xuanmei Ye, Jialu Huang, Quanzi Chen, Jing Xu, Minghua Jiang, Wang Jia, Qipeng Xie

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaoxiao QuDepartment of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Guanhong LiMedical Laboratory Technology, Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Hongqun TaoDepartment of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Xuanmei YeDepartment of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Jialu HuangDepartment of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Quanzi ChenDepartment of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Jing XuDepartment of Endocrinology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Minghua JiangDepartment of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Wang JiaDepartment of Critical Care Medicine, The Second People's Hospital of Zhaotong, Zhaotong, 657000, Yunnan, China. 924672896@qq.com.
Qipeng XieDepartment of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China. xieqipeng@wmu.edu.cn.ORCID 0000-0002-3292-2988

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile visceral adiposity and lipid dysregulation are established drivers of metabolic dysfunction-associated steatotic liver disease (MASLD), the clinical utility of the lipid accumulation product (LAP) for identifying prevalent MASLD in patients with type 2 diabetes mellitus (T2DM) remains insufficiently characterized. This study aimed to characterize the dose-response relationship between LAP and MASLD in T2DM, establish optimal sex-specific diagnostic thresholds, and evaluate its clinical net benefit to guide non-invasive screening.

methodsThis study included 495 inpatients with T2DM. log

resultsThrough a systematic feature-selection approach using the Boruta algorithm, log

conclusionslog

Indexed as

Diabetes Mellitus, Type 2Lipid Accumulation ProductLipidsAdultAgedBiomarkersDecision Support TechniquesFemaleHumansMaleMiddle AgedPredictive Value of TestsPrevalencePrognosisReproducibility of ResultsRisk AssessmentBiomarkersLipidsDecision curve analysisLipid accumulation productMASLDSex-specific cut-offsSubgroup analysisType 2 diabetes mellitus

Identifiers

PMID42116040
PMCPMC13335321

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.